celecoxib Articles
Merck & Co warned over Vioxx promotion
25 September 2001
Datamonitor expresses views on Celebrex vs Vioxx; Novartis ADHD drug
24 September 2001
Stock Commentary - Europe
6 September 2001
Stock Commentary - Europe
30 August 2001
Pharmacia earnings up 20%, sales rise 5%
25 July 2001
US state seniors Rx costs compared globally
18 July 2001
Update - Pfizer second-quarter net income leaps 31%
18 July 2001
Japan pharma stocks - week to July 9
11 July 2001
Rite Aid cuts prices for Rx cash buys
27 June 2001
Pharmacia slams price of Celebrex in Australia
25 June 2001
Celebrex' efficacy and safety; new data
21 June 2001
Merckle unveils Phase II data on coxib rival
21 June 2001
US seniors' Rx cost rises "are double inflation"
15 June 2001
Australian PBS must be more transparent: govt
5 June 2001
Stock Commentary - New York
31 May 2001
Yamanouchi sets out five-year strategy
30 April 2001
Celebrex gets closer to revised label in USA
17 April 2001
Tokyo pharma stock market - week to April 2
4 April 2001
Pharmacia files for follow-up COX-2 OK
23 March 2001
Informa Pharma Award winners
21 March 2001
Update - Celebrex and Vioxx panel review on COX-2 inhibitors
15 February 2001
Stock Commentary - Tokyo
15 February 2001
Pharmacia fourth-quarter earnings jump 32%, driven by Celebrex sales
13 February 2001
Celebrex fails to gain label change backing
8 February 2001
Pharmacia revises Celebrex TV ad after FDA rap
14 December 2000
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
Merck & Co reiterates independence at pipeline presentation
14 December 2000
Stock Commentary - Tokyo
30 November 2000
Stock Commentary - Tokyo
16 November 2000
Yamanouchi sales up on forecasts
13 November 2000
Falling US sales for high-profile drugs
8 November 2000
UK's low uptake of COX-2 inhibitors: study
11 October 2000
Bullish forecast for pharma industry from Merrill Lynch, despite patent
29 September 2000
Cell Pathways' Aptosyn deemed not approvable by FDA for FAP
25 September 2000
COX-2 inhibitors to treat prostate cancer?
21 September 2000
Pfizer/Pharmacia's Celebrex tops leading NSAIDs in GI safety study
15 September 2000
Pharmacia plans for Japanese market
21 July 2000
Pharmacia completes Spanish restructuring
19 July 2000
Pfizer leads 1st-qtr US physician detailing
11 July 2000
Yamaanouci looks to Lipitor for future growth
24 May 2000
Pharmacia/Merck to seek warning removal
11 May 2000
Pharmacia's EPS up 27% in 1st quarter
26 April 2000
Once-daily Celebrex as effective as twice-daily
14 April 2000
Merck wins another victory in COX-2 battle
5 April 2000
Sankyo discusses new COX-2 inhibitor with analysts
7 March 2000
Celebrex sets record for launch
24 February 2000
Pharmacia & Upjohn and Monsanto both post strong results for 1999
11 February 2000
Merck & Co wins UK patent dispute with Searle
8 February 2000
Six largest US PBMs place Celebrex on national formularies
20 January 2000
Pfizer EPS in 4th qtr rises 56%
18 January 2000
Cell Pathways' Aptosyn, "no review by ODAC"
14 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Celebrex to be promoted for polyposis
29 December 1999
Mixed reaction to P&U and Monsanto's planned merger
21 December 1999
BI gets approvable letter for Mobic in USA
21 December 1999
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
